Indoco Remedies Limited, a prominent pharmaceutical company, has announced a strategic sale and leaseback agreement valued at ₹24.65 crore with OPC Asset Solution Private Limited. The deal encompasses part of the company's movable properties at its Waluj facility in Aurangabad, Maharashtra, and the AnaCipher Clinical Research Organisation (CRO) in Hyderabad, Telangana.

Key Details of the Agreement

• Sale Agreement: Indoco Remedies will sell part of its movable properties at the Waluj Facility and CRO to OPC Asset Solution for a total consideration of ₹24.65 crore (including GST).
• Lease Agreement: The company will lease back the same properties from OPC Asset Solution.
• Lease Duration: The lease arrangement extends from August 29, 2025, to September 30, 2035, a period of 10 years and 33 days.
• Lease Fees: The total lease fees for the entire tenure amount to ₹34.89 crore (including taxes).
• Security Deposit: Indoco Remedies will pay a security deposit of ₹2.46 crore for the leased properties.

Impact on Operations

Indoco Remedies has assured that this sale-leaseback arrangement will not affect its manufacturing or business operations. The company will continue to use the movable properties on a lease basis, ensuring uninterrupted functionality at both the Waluj Facility and the CRO.

Regulatory Compliance

The company has made this disclosure in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It's worth noting that this transaction does not fall under related party transactions, and there are no special rights or potential conflicts of interest arising from the agreements.

Strategic Implications

This sale-leaseback deal appears to be a strategic financial move by Indoco Remedies, potentially aimed at unlocking capital from its assets while maintaining operational control. Such arrangements can provide companies with increased financial flexibility and improved cash flow management.

The pharmaceutical sector continues to see companies optimizing their asset portfolios, and Indoco Remedies' latest move aligns with this industry trend. As the company moves forward with this arrangement, stakeholders will likely be keen to observe how it leverages the freed-up capital for future growth initiatives or operational improvements.

Indoco Remedies , a prominent player in the pharmaceutical industry, has achieved a significant milestone in its expansion into the U.S. market. The company announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban tablets.

Key Highlights

• Indoco Remedies has obtained USFDA approval for Rivaroxaban tablets in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg.
• The approved generic is bioequivalent and therapeutically equivalent to Janssen Pharmaceuticals' Xarelto tablets.
• Rivaroxaban is primarily used for the treatment of venous thromboembolism (VTE).
• The tablets will be manufactured at Indoco's facility in Verna, Goa.

Strategic Importance

This regulatory approval marks a crucial step for Indoco Remedies, allowing the company to manufacture and market the generic version of Rivaroxaban in the United States. The move is expected to strengthen Indoco's position in the competitive U.S. pharmaceutical market.

Ms. Aditi Panandikar, Managing Director of Indoco Remedies, commented on the achievement, stating, "Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US."

About Indoco Remedies

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. Key facts about the company include:

• Annual turnover of approximately US$ 180.00 million
• Workforce of over 6,000 employees, including more than 400 skilled scientists
• 11 manufacturing facilities (7 for finished dosage forms and 4 for active pharmaceutical ingredients)
• State-of-the-art R&D Center and CRO facility
• Approvals from major regulatory authorities, including USFDA and UK-MHRA
• 10 domestic marketing divisions with a strong brand portfolio in various therapeutic segments
• International partnerships with large generic companies globally

The approval of Rivaroxaban tablets adds to Indoco's growing portfolio of FDA-approved products and underscores the company's commitment to expanding its presence in the U.S. generic drug market. This development is expected to contribute positively to Indoco Remedies' growth trajectory in the coming years.